查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827938

獸用疫苗市場（依產品類型、動物類型、給藥途徑、疾病類型和分銷管道分類）－2025-2032 年全球預測

Veterinary Vaccines Market by Product Type, Animal Type, Route Of Administration, Disease Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，獸用疫苗市場將成長至 241.5 億美元，複合年成長率為 6.93%。

主要市場統計數據
基準年2024年 141.3億美元
預計2025年 150.5億美元
預測年份：2032年 241.5億美元
複合年成長率（%） 6.93%

對動物疫苗現狀、主要需求促進因素、技術變革和相關人員的策略重點進行引人注目且全面的介紹

動物疫苗處於生物技術、動物福利和全球貿易動態的交匯點，其相關人員涵蓋從研究機構到第一線獸醫診所的各個領域。本導論探討了推動近期決策的核心主題，包括抗原設計和遞送的科學創新、跨動物物種的疾病負擔變化，以及依賴低溫運輸的生技藥品的運作現狀。本書以科學和商業性觀點觀點基礎，為讀者提供將實驗室進展轉化為臨床成果和供應鏈執行的實用指導。

此外，引言部分概述了影響項目可行性和應用的關鍵因素，包括不斷變化的免疫抗原性和安全性監管預期、伴侶動物和牲畜干預措施的經濟性，以及分銷網路在確保及時獲取方面的作用。引言部分著重於實踐見解而非抽象的趨勢，並闡述了後續分析如何為研發、生產和商業團隊的策略選擇提供參考。

快速的技術創新、不斷變化的動物保健模式、不斷發展的監管環境以及新的商業模式如何重塑動物疫苗格局和價值鏈

獸用疫苗領域正在經歷變革時期。分子生物學和載體工程的發展正在加速下一代平台的開發，包括次單元、重組和病毒載體方法，從而擴展了控制複雜病毒和寄生蟲疾病的套件。同時，佐劑科學和製劑技術的進步使得製劑更加穩定，並減少了劑量。

同時，監管機構正在調整框架，以應對優先動物健康威脅的新模式和快速途徑。這種監管變革既帶來了機遇，也帶來了複雜性。某些化合物的快速核准流程與人們對上市後監測和批次放行數據的更高期望相平衡。在商業性，數位化獸醫服務和線上分銷管道正在再形成疫苗到達最終用戶的方式，而遠端醫療和電子商務正在改變伴侶動物疫苗的需求模式，並創造替代的市場途徑。最後，對「同一健康」的日益觀點正在使公共和私營部門的優先事項圍繞著降低通用感染疾病風險進行協調。

評估 2025 年美國關稅對進口、供應連續性、定價權和下游獸醫服務的累積營運、成本和貿易影響

2025年實施的貿易措施和關稅調整為獸用疫苗生產所用生技藥品和輔助材料的全球供應鏈帶來了新的摩擦。這些措施改變了以往以較低關稅跨境運輸的進口投入的計算方式，尤其是試劑、特殊黏合劑、一次性組件和成品。為此，製造商和經銷商重新評估了籌資策略，加快了供應商資格認證計劃，並考慮將關鍵供應線區域化，以降低受貿易相關成本波動影響的風險。

在營運方面，關稅凸顯了本地製造能力和倉儲彈性的重要性。擁有現有區域生產基地的公司能夠更有效地降低風險，而依賴遠距進口的公司則面臨更長的前置作業時間時間和更高的到岸成本。政策環境也促使合約重新談判，並更多地使用外匯和採購對沖策略。對於臨床和商業團隊而言，實際結果是，他們重新將產品系列放在優先考慮能夠保持供應可靠性和成本可預測性的地區，同時探索合作夥伴關係和許可，以實現針對特定區域的灌裝和分銷，從而在不斷變化的貿易體制中保持市場進入。

深入的細分洞察揭示了產品類型、動物類別、給藥途徑、疾病目標和分銷管道如何轉化為臨床應用和商業策略

細緻入微地了解市場區隔對於使產品策略與臨床需求和商業性可行性保持一致至關重要。產品類型包括去活化疫苗、減毒活病毒疫苗、次單元疫苗、重組疫苗以及病毒載體疫苗，每種疫苗的開發時間表、安全性和低溫運輸依賴性各不相同，這些都會影響市場部署選擇。伴侶動物市場主要集中在貓和狗，強調便利性、安全性和飼主主導的購買行為。同時，在畜牧業中，規模效益和監管監督決定了採用動態，優先考慮牛、家禽、羊和豬的群體級疾病控制。

給藥途徑進一步區分，口服、腸胃外和局部製劑在給藥的簡易性、免疫反應品質和製劑複雜性之間提供各種權衡。細菌、感染疾病、寄生蟲和病毒感染疾病的疫苗需要不同的設計和給藥策略。細菌感染疾病包括大腸桿菌病、結腸感染疾病症候群、鉤端螺旋體病和巴氏桿菌症，每種感染都需要最佳化目標抗原，通常還需要佐劑。寄生蟲感染疾病既針對體外寄生蟲也針對體內寄生蟲，需要在疫苗保護與環境和管理控制之間取得平衡。病毒疫苗針對的病毒種類繁多，從禽流感病毒到牛病毒性腹瀉病毒、口蹄疫病毒、新城疫病毒、豬繁殖與呼吸綜合症病毒和狂犬病毒，每種病毒都有其自身的免疫學挑戰和監管考慮。最後，分銷管道動態——透過線上藥局、零售藥局和獸醫診所——影響著商業性執行。診所直接分銷有利於醫生的影響力和低溫運輸管理，零售藥局為消費者提供便利，而線上藥局則開闢了新的購買途徑，需要數位化物流和疫苗產品的信任建立。

區域情報重點介紹美洲、歐洲、中東和非洲地區以及亞太地區的不同需求促進因素、監管細節、製造地和分銷挑戰

地理動態顯著影響疫苗研發重點、監管策略和分銷方式。美洲地區擁有強大的獸醫基礎設施、較高的伴侶動物收養率以及​​成熟的商業管道，支持高級產品和數位化分銷模式的快速普及。該地區的生產商正在利用先進的低溫運輸物流來支援複雜的生技藥品，同時越來越重視生命週期數據和上市後安全監測。

在歐洲、中東和非洲，監管協調工作與生產能力和購買力的巨大差異並存。該地區需要靈活的策略來應對某些市場嚴格的監管預期，以及其他市場產能增加或成本驅動的模式。同時，亞太地區擁有大規模畜牧生產系統、新興製造地和日益壯大的伴侶動物養殖業，這不僅創造了大規模生產的機會，也帶來了對可擴展、本地化客製化供應解決方案的需求。在所有地區，本地監管途徑、進口限制和分銷基礎設施仍然是新型動物疫苗產品商業規劃和部署的關鍵因素。

分析領先開發商、生技藥品製造商、委託製造、經銷商和服務供應商之間的競爭和合作行為，塑造策略定位和創新

獸用疫苗領域的競爭態勢由擁有深厚研發實力、生產規模和分銷網路的公司所塑造。其中一條策略軸線是將公司分類為兩類：一類公司大力投資專有平台技術和產品線多元化，另一類公司則專注於利基市場或合約服務，例如填充和低溫運輸物流。夥伴關係和授權協議是彌補能力差距的常用機制。專注於研究的機構經常與大型製造商合作，以加速商業化進程，而區域經銷商和臨床網路則提供市場滲透能力。

另一個重要趨勢是製造外包和專業生技藥品服務提供者的角色日益增強，這使得規模較小的創新企業無需大量資本投入即可擴大規模。次單元和病毒載體尤其需要專業的製程專業知識。從商業策略角度來看，將臨床證據產生與務實的分銷模式（確保為最終用戶提供合適的包裝、標籤和低溫運輸完整性）相結合的公司往往能獲得更廣泛的從業者認可和採用。最後，隨著業界尋求提高整個價值鏈的效率，解決低溫運輸標準化、監管協調和上市後監管等跨領域問題的合作措施變得越來越重要。

為產業領導者提供具影響力的策略建議，以加速疫苗創新、增強供應彈性、最佳化市場進入並改善跨通路的商業性執行。

領導者應優先考慮一系列切實有效、卓有成效的措施，以應對當前環境並抓住機會。首先，投資平台多功能性和模組化製造能力，以快速適應不同的抗原類型和劑型。其次，加強供應商多元化和資格確認計劃，以降低關稅帶來的採購風險。這包括與合格的契約製造和本地灌裝合作夥伴建立關係，以便在貿易政策變化時保持連續性。

第三，我們將儘早調整監管策略，使其與目標市場需求一致，並規劃強而有力的上市後監管，以滿足不斷變化的安全預期。透過平行磋商與監管機構合作，可以縮短創新模式的核准途徑。第四，我們將透過協調伴侶動物和牲畜管道的分銷方式、在適當情況下整合數位銷售和遠端醫療，以及確保為獸醫和輔助專業人員提供實地培訓，來改善控制和合規性，最佳化商業模式。最後，我們將開展舉措，增強相關人員的信心，並透過提高低溫運輸韌性和共用不利事件監測數據平台，支援下一代疫苗的快速部署。

一種強大的混合調查方法，結合主要相關人員調查、二手文獻綜合和嚴格的數據三角測量，以確保分析的有效性和可重複性。

本研究的基礎研究採用了混合方法，旨在兼顧深度和相關性。主要研究包括與科學研究領導者、監管專家、生產高管和分銷合作夥伴進行結構化訪談，以突出實際限制和未來重點。這些定性資訊為專題研究的重點提供了資訊，並指南了有針對性的後續研究，以明確技術依賴性和商業性考慮。除了主要資訊外，我們還廣泛整合了同行評審文獻、監管指南文件和行業白皮書，為平台和疾病特異性分析提供了技術基礎。

我們運用資料三角檢定來協調資訊來源之間的差異並檢驗推論的結論。在可能的情況下，技術聲明由多個獨立相關人員進行佐證，以減少偏差。調查方法強調預測假設的透明度和記錄的分析界限，包括排除推測性預測和專有財務指標。此外，我們反覆進行同儕審查，以確保臨床、生產和商業性解讀的穩健性並與現行實踐保持一致。

簡要概括策略要點、突出挑戰和近期優先事項，供高階決策者在應對不斷發展的動物疫苗生態系統時採取行動

本分析綜合了技術進步、法規演變、市場區隔現狀、區域動態以及貿易政策變化對獸用疫苗產業的策略影響。關鍵要點包括：平衡技術創新與營運韌性的必要性、區域製造和分銷敏捷性的策略價值，以及基於細分市場的產品策略的重要性，該策略反映了伴侶動物市場和畜牧市場之間的差異。總而言之，這些見解表明，在平台、供應鏈多元化和監管參與方面的戰術性投資，能夠在市場進入和臨床應用方面獲得豐厚回報。

展望未來，決策者不應將疫苗研發視為線性產品計劃，而應將其視為一個整合科學、製造、監管和現場執行的生態系統挑戰。這樣做將使研發投資與更切合實際的落地路徑保持一致，減少外部衝擊的影響，並加速科學進步轉化為可衡量的動物健康成果。因此，這個結論強調了將技術進步轉化為永續商業性優勢的綜合、跨職能方法的必要性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 擴大使用基於mRNA的獸用疫苗來對抗新出現的牲畜疾病
  • 將人工智慧驅動的診斷技術整合到疫苗開發平臺中，以加快核准時間
  • 擴大多種病原體的聯合疫苗，以減少家禽的接種頻率
  • 開發耐熱疫苗製劑以提高偏遠地區的低溫運輸耐受性
  • 針對特定族群健康管理和疫情控制的自體疫苗需求不斷增加
  • 增加對奈米顆粒疫苗佐劑的投資，以增強牲畜的免疫反應

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章：動物疫苗市場（依產品類型）

  • 去活化疫苗
  • 減毒活疫苗
  • 次單位疫苗和重組疫苗
  • 病毒載體疫苗

9. 動物疫苗市場（依動物類型）

  • 伴侶動物
    • 貓
    • 狗
  • 家畜
    • 牛
    • 家禽
    • 羊
    • 豬

第 10 章：按管理途徑分類的動物疫苗市場

  • 口服
  • 腸外
  • 話題

第 11 章：動物疫苗市場（依疾病類型）

  • 細菌感染疾病
    • 梭菌
    • 大腸桿菌
    • 鉤端螺旋體病
    • 巴氏桿菌
  • 黴菌感染疾病
  • 寄生蟲感染疾病
    • 體外寄生蟲
    • 體內寄生蟲
  • 病毒感染
    • 禽流感病毒
    • 牛病毒性腹瀉病毒（BVDV）
    • 口蹄疫病毒（FMDV）
    • 新城疫病毒
    • 豬繁殖與呼吸綜合症病毒（PRRSV）
    • 狂犬病毒

第 12 章：動物疫苗市場（依通路）

  • 網路藥局
  • 零售藥局
  • 獸醫診所

第 13 章：獸用疫苗市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章：動物疫苗市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。按國家/地區分類的動物疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Arko Corp.
    • Bimeda Biologicals Inc
    • Biogenesis Bago SA
    • Boehringer Ingelheim International GmbH
    • Ceva Sante Animale
    • Dechra Pharmaceuticals PLC
    • Elanco Animal Health Incorporated
    • Endovac Animal Health
    • Hester Biosciences Limited
    • Hipra SA
    • Huvepharma, Inc.
    • Indian Immunologicals Ltd.
    • Kemin Industries, Inc.
    • Merck & Co., Inc.
    • Neogen Corporation
    • Pfizer, Inc.
    • Phibro Animal Health Corporation
    • SAN Group Biotech Germany GmbH
    • Seppic by Air Liquide Healthcare
    • SK Bioscience
    • Vaxxinova
    • Virbac SA
    • Zoetis Inc.
Product Code: MRR-4316E4E89380

The Veterinary Vaccines Market is projected to grow by USD 24.15 billion at a CAGR of 6.93% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 14.13 billion
Estimated Year [2025] USD 15.05 billion
Forecast Year [2032] USD 24.15 billion
CAGR (%) 6.93%

A compelling, comprehensive introduction that frames the current state of veterinary vaccines, key demand drivers, technological inflections, and strategic priorities for stakeholders globally

The veterinary vaccines domain sits at the intersection of biotechnology, animal welfare, and global trade dynamics, with stakeholders ranging from research laboratories to frontline veterinary practices. This introduction frames the core themes that drive near-term decision-making: scientific innovation in antigen design and delivery, shifting disease burdens across species, and the operational realities of cold-chain dependent biologics. By grounding the narrative in both scientific and commercial perspectives, readers gain a practical orientation that links laboratory advances to clinic-level outcomes and supply-chain execution.

In addition, the introduction outlines the primary levers that influence program viability and adoption. These include evolving regulatory expectations for immunogenicity and safety, the economics of companion animal versus livestock interventions, and the role of distribution networks in ensuring timely access. Taken together, the early section establishes the analytical lens used throughout the study, emphasizing actionable insights over abstract trends and setting expectations for how subsequent analysis will translate into strategic choices for R&D, manufacturing, and commercial teams.

How rapid technological innovation, shifting animal health paradigms, evolving regulatory frameworks, and new commercial models are together reshaping the veterinary vaccines landscape and value chains

The landscape of veterinary vaccines is undergoing a period of transformative change driven by multiple, interlocking forces. Advances in molecular biology and vector engineering have accelerated the development of next-generation platforms such as subunit, recombinant, and viral vector approaches, expanding the toolkit available to control complex viral and parasitic diseases. Concurrently, improvements in adjuvant science and formulation technologies are enabling more stable products with reduced dosing requirements, which in turn affect logistics, dosing regimens, and uptake among practitioners.

At the same time, regulatory authorities are adapting frameworks to accommodate novel modalities and expedited pathways for high-priority animal health threats. This regulatory evolution is producing both opportunities and complexities: faster pathways for certain constructs are balanced by heightened expectations for post-market surveillance and batch-release data. Commercially, digital veterinary services and online distribution channels are reshaping how vaccines reach end users, with telemedicine and e-commerce altering demand patterns for companion animal vaccines and creating alternate routes to market. Finally, growing emphasis on One Health perspectives is aligning public and private priorities around zoonotic risk mitigation, which increases collaboration across human and animal health domains and elevates investment in vaccines that reduce cross-species transmission.

Assessing the cumulative operational, cost and trade impacts of the United States tariffs enacted in 2025 on imports, supply continuity, pricing dynamics, and downstream veterinary services

The imposition of trade measures and tariff adjustments in 2025 introduced new friction into global supply chains for biologics and ancillary materials used in veterinary vaccine manufacture. These measures have changed the calculus for imported inputs, particularly reagents, specialty adhesives, single-use components, and finished-dose products that historically moved across borders with lower tariff exposure. In response, manufacturers and distributors have reassessed sourcing strategies, accelerated supplier qualification programs, and explored regionalization of critical supply lines to reduce vulnerability to trade-related cost volatility.

Operationally, the tariffs have amplified the importance of local manufacturing capacity and warehousing agility. Firms with pre-existing regional production hubs were able to mitigate exposure more effectively, whereas organizations reliant on long-haul imports faced longer lead times and higher landed costs. The policy environment has also encouraged contractual renegotiations and greater use of hedging strategies for currency and procurement. For clinical and commercial teams, the practical outcome has been a renewed focus on prioritizing product portfolios for geographies where supply reliability and cost predictability can be maintained, while exploring partnerships and licensing that allow for localized fill-finish and distribution to preserve market access under changing trade regimes.

Deep segmentation insights revealing how product types, animal categories, administration routes, disease targets, and distribution channels collectively inform clinical adoption and commercial strategies

A nuanced understanding of market segmentation is essential to align product strategy with clinical need and commercial feasibility. Based on product type, the domain includes Inactivated Vaccines, Live Attenuated Vaccines, Subunit & Recombinant Vaccines, and Viral Vector Vaccines, each presenting distinct development timelines, safety profiles, and cold-chain dependencies that influence go-to-market choices. When examined by animal type, the market divides between Companion Animals and Livestock Animals; companion animal work largely concentrates on Cats and Dogs with emphasis on convenience, safety and owner-driven purchasing behavior, while livestock efforts prioritize herd-level disease control across Cattle, Poultry, Sheep, and Swine with scale efficiencies and regulatory oversight shaping adoption dynamics.

Route of administration introduces further differentiation, with Oral, Parenteral, and Topical delivery pathways offering varying trade-offs between ease of administration, immune response quality, and formulation complexity. Disease-type considerations add another strategic layer: vaccines targeting Bacterial Infections, Fungal Infections, Parasitic Infections, and Viral Infections must be designed and communicated differently. Bacterial indications encompass Clostridial illness, E. coli syndromes, Leptospirosis, and Pasteurella, each requiring targeted antigens and often adjuvant optimization. Parasitic disease work addresses both Ectoparasites and Endoparasites, where vaccine-induced protection must be balanced against environmental and management controls. Viral vaccine targets range from Avian Influenza Virus to Bovine Viral Diarrhea Virus, Foot-and-Mouth Disease Virus, Newcastle Disease Virus, Porcine Reproductive & Respiratory Syndrome Virus, and Rabies Virus, each presenting unique immunological challenges and regulatory considerations. Finally, distribution channel dynamics across Online Pharmacies, Retail Pharmacies, and Veterinary Clinics shape commercial execution: direct clinic distribution favors practitioner influence and cold-chain stewardship, retail pharmacies offer consumer convenience, and online pharmacies create new purchasing pathways that require digital logistics and trust-building for vaccine products.

Region-focused intelligence highlighting differentiated demand drivers, regulatory nuances, manufacturing hubs, and distribution challenges across the Americas, EMEA, and Asia-Pacific regions

Geographic dynamics materially influence vaccine development priorities, regulatory strategy, and distribution approaches. In the Americas, strong veterinary infrastructure, high companion animal ownership rates, and established commercial channels favor rapid adoption of premium products and digital distribution models. Producers in this region increasingly emphasize lifecycle data and post-market safety monitoring while leveraging sophisticated cold-chain logistics to support complex biologics.

Across Europe, Middle East & Africa, regulatory harmonization efforts coexist with wide heterogeneity in manufacturing capacity and purchasing power. This region demands flexible strategies that accommodate stringent regulatory expectations in some markets alongside capacity-building and cost-sensitive models in others. Meanwhile, Asia-Pacific reflects a mix of large-scale livestock production systems, emergent manufacturing hubs, and rising companion animal ownership that together create both high-volume opportunities and the need for scalable, locally adapted supply solutions. Across all regions, local regulatory pathways, import controls, and distribution infrastructures remain decisive factors in the commercial planning and rollout of new veterinary vaccine products.

Competitive and collaborative behavior analysis among leading developers, biologics formulators, contract manufacturers, distributors, and service providers shaping strategic positioning and innovation

Competitive dynamics in the veterinary vaccines space are shaped by companies that combine R&D depth, manufacturing scale, and distribution reach. One strategic axis separates organizations that invest heavily in proprietary platform technologies and pipeline diversity from those that focus on niche indications or contract services such as fill-finish and cold-chain logistics. Partnerships and licensing agreements serve as common mechanisms to bridge capability gaps: research-focused entities frequently collaborate with large-scale manufacturers to expedite commercial access, while regional distributors and clinical networks provide market penetration capacity.

Another important trend is the increasing role of contract manufacturing and specialized biologics service providers that enable smaller innovators to scale without extensive capital investment. These arrangements influence time-to-market and create modular paths to commercialization, especially for subunit and viral vector constructs that demand specific process expertise. From a commercial strategy perspective, companies that align clinical evidence generation with pragmatic distribution models-ensuring appropriate packaging, labeling and cold-chain integrity for end users-tend to achieve better practitioner acceptance and uptake. Finally, collaborative initiatives that address cross-cutting challenges such as cold-chain standardization, regulatory harmonization, and post-market surveillance are becoming more prominent as the industry seeks efficiencies across the value chain.

High-impact strategic recommendations for industry leaders to accelerate vaccine innovation, strengthen supply resilience, optimize market access, and improve commercial execution across channels

Leaders should prioritize a set of pragmatic, high-impact measures to navigate the current environment and capture opportunity. First, invest in platform versatility and modular manufacturing capabilities that allow rapid reconfiguration for different antigen types and dosing formats; this reduces time-to-clinic and supports regional production strategies. Second, strengthen supplier diversification and qualification programs to mitigate tariff-driven sourcing risks, including building relationships with qualified contract manufacturers and local fill-finish partners to preserve continuity under shifting trade policies.

Third, align regulatory strategies early with target market requirements and plan for robust post-market surveillance to satisfy evolving safety expectations; engaging with regulators through parallel consultations can shorten approval pathways for innovative modalities. Fourth, optimize commercial models by tailoring distribution approaches for companion animal versus livestock channels, integrating digital sales and telemedicine where appropriate, and ensuring field-level training for veterinarians and paraprofessionals to improve administration and compliance. Lastly, pursue collaborative initiatives that advance cold-chain resilience and shared data platforms for adverse event monitoring, which will enhance stakeholder confidence and support more rapid adoption of next-generation vaccines.

Robust mixed-methods research methodology combining primary stakeholder engagement, secondary literature synthesis, and rigorous data triangulation to ensure analytical validity and reproducibility

The research underpinning this study follows a mixed-methods approach designed to balance depth and validity. Primary engagement included structured interviews with scientific leaders, regulatory specialists, manufacturing executives, and distribution partners to surface practical constraints and forward-looking priorities. These qualitative inputs informed thematic priorities and guided targeted follow-ups that clarified technical dependencies and commercial considerations. Alongside primary input, an extensive synthesis of peer-reviewed literature, regulatory guidance documents, and industry whitepapers provided the technical foundation for platform-specific and disease-targeted analysis.

Data triangulation was applied to reconcile differences across sources and to validate inferred conclusions. Where possible, technical assertions were corroborated by multiple independent stakeholders to reduce bias. The methodology emphasizes transparency in assumptions and documents analytical boundaries, including the exclusion of speculative forecasts or proprietary financial metrics. In addition, the study incorporated iterative reviews by subject matter experts to ensure that clinical, manufacturing, and commercial interpretations remain robust and aligned with current practice.

Concise synthesis of strategic takeaways, unresolved challenges, and near-term priorities that senior decision-makers should act on to navigate the evolving animal vaccine ecosystem

This analysis synthesizes the strategic implications of technological progress, regulatory evolution, segmentation realities, regional dynamics, and trade policy shifts for the veterinary vaccines sector. Key takeaways include the imperative to balance innovation with operational resilience, the strategic value of regional manufacturing and distribution agility, and the importance of segmentation-informed product strategies that reflect differences between companion animal and livestock markets. Collectively, these insights underscore that tactical investments in platforms, supply chain diversity, and regulatory engagement deliver outsized returns in market access and clinical uptake.

Looking ahead, decision-makers should treat vaccine development not as a linear product project but as an ecosystem challenge that integrates science, manufacturing, regulation, and field execution. By doing so, organizations can better align R&D investments to practical adoption pathways, reduce exposure to external shocks, and accelerate the translation of scientific advances into measurable animal health outcomes. The conclusion therefore reinforces the need for integrated, cross-functional approaches that convert technical advances into durable commercial advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing use of mRNA-based veterinary vaccines to address emerging livestock diseases
  • 5.2. Integration of AI-driven diagnostics in vaccine development pipelines for faster approval times
  • 5.3. Expansion of combination vaccines targeting multiple pathogens to reduce dosing frequency in poultry
  • 5.4. Growth of thermostable vaccine formulations to improve cold chain resilience in remote regions
  • 5.5. Rising demand for autogenous vaccines tailored for specific herd health management and outbreak control
  • 5.6. Increased investment in nanoparticle vaccine adjuvants to enhance immune response in livestock species

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Vaccines Market, by Product Type

  • 8.1. Inactivated Vaccines
  • 8.2. Live Attenuated Vaccines
  • 8.3. Subunit & Recombinant Vaccines
  • 8.4. Viral Vector Vaccines

9. Veterinary Vaccines Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
  • 9.2. Livestock Animals
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep
    • 9.2.4. Swine

10. Veterinary Vaccines Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Veterinary Vaccines Market, by Disease Type

  • 11.1. Bacterial Infections
    • 11.1.1. Clostridial
    • 11.1.2. E. Coli
    • 11.1.3. Leptospirosis
    • 11.1.4. Pasteurella
  • 11.2. Fungal Infections
  • 11.3. Parasitic Infections
    • 11.3.1. Ectoparasites
    • 11.3.2. Endoparasites
  • 11.4. Viral Infections
    • 11.4.1. Avian Influenza Virus
    • 11.4.2. Bovine Viral Diarrhea Virus (BVDV)
    • 11.4.3. Foot-and-Mouth Disease Virus (FMDV)
    • 11.4.4. Newcastle Disease Virus
    • 11.4.5. Porcine Reproductive & Respiratory Syndrome Virus (PRRSV)
    • 11.4.6. Rabies Virus

12. Veterinary Vaccines Market, by Distribution Channel

  • 12.1. Online Pharmacies
  • 12.2. Retail Pharmacies
  • 12.3. Veterinary Clinics

13. Veterinary Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Veterinary Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Veterinary Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Arko Corp.
    • 16.3.2. Bimeda Biologicals Inc
    • 16.3.3. Biogenesis Bago S.A.
    • 16.3.4. Boehringer Ingelheim International GmbH
    • 16.3.5. Ceva Sante Animale
    • 16.3.6. Dechra Pharmaceuticals PLC
    • 16.3.7. Elanco Animal Health Incorporated
    • 16.3.8. Endovac Animal Health
    • 16.3.9. Hester Biosciences Limited
    • 16.3.10. Hipra S.A.
    • 16.3.11. Huvepharma, Inc.
    • 16.3.12. Indian Immunologicals Ltd.
    • 16.3.13. Kemin Industries, Inc.
    • 16.3.14. Merck & Co., Inc.
    • 16.3.15. Neogen Corporation
    • 16.3.16. Pfizer, Inc.
    • 16.3.17. Phibro Animal Health Corporation
    • 16.3.18. SAN Group Biotech Germany GmbH
    • 16.3.19. Seppic by Air Liquide Healthcare
    • 16.3.20. SK Bioscience
    • 16.3.21. Vaxxinova
    • 16.3.22. Virbac S.A.
    • 16.3.23. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL VETERINARY VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. VETERINARY VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. VETERINARY VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VETERINARY VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VETERINARY VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VETERINARY VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFR